经皮腔内血管成形术治疗膝下慢性肢体威胁性缺血:一期通畅率与二分类再狭窄率的系统评价与Meta分析
该系统评价与Meta分析纳入17项以经皮腔内血管成形术(PTA)为对照臂的随机对照试验(1048例患者、1279处病变),汇总6项RCT数据的一期通畅率6个月为68%(95%CI 45%-84%)、12个月为66%(95%CI 51%-79%);汇总11项RCT数据的二分类再狭窄率6个月为54%(95%CI 33%-73%)、9至12个月为60%(95%CI 39%-78%)。所有结局均存在显著异质性(I²>50%,p<0.0001),未观察到发表偏倚(Egger检验p>0.1)。
要点
- PTA治疗膝下CLTI的12个月一期通畅率汇总为66%(95%CI 51%-79%)。
- PTA术后9至12个月二分类再狭窄率汇总为60%(95%CI 39%-78%)。
- 上述1年通畅率较历史用于功效计算的值高10%至20%。
核心结论
- 该Meta分析利用前瞻性收集、以核心实验室裁定为主的RCT数据,提供了PTA术后二分类再狭窄率与一期通畅率的估计值。
- 结果显示1年一期通畅率较历史上用于功效计算的值高10%至20%,这些新估计值有助于为未来RCT进行更准确的功效分析。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、EMBASE、Cochrane Central及ClinicalTrials.gov截至2022年11月的RCT。
- 纳入以PTA为对照臂且包含膝下CLTI患者的RCT,共17项RCT(1048例患者、1279处病变)。
- 排除标准包括>25%患者为间歇性跛行、纳入其他血管、或未将一期通畅率或二分类再狭窄率作为结局的研究。
- 采用随机效应模型分析,研究方案在PROSPERO公开注册(ID#394543),未使用任何资助。
主要发现
- 基于6项RCT数据,汇总一期通畅率6个月为68%(95%CI 45%-84%),12个月为66%(95%CI 51%-79%)。
- 基于11项RCT数据,汇总二分类再狭窄率6个月为54%(95%CI 33%-73%),9至12个月为60%(95%CI 39%-78%)。
- 所有结局均存在显著异质性(I²>50%,p<0.0001)。
- 未观察到发表偏倚(Egger检验p>0.1)。
关键数值与推荐
- 1年一期通畅率汇总为66%(95%CI 51%-79%,基于6项RCT)。
- 9至12个月二分类再狭窄率汇总为60%(95%CI 39%-78%,基于11项RCT)。
- 历史用于功效计算的一期通畅率估计为40%至50%、二分类再狭窄率估计为45%至65%。
临床怎么用
- 作者认为这些新估计值有助于为未来膝下CLTI的RCT进行更准确的功效分析。
局限性
- 所有结局均存在显著异质性(I²>50%,p<0.0001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Percutaneous transluminal angioplasty (PTA) remains the mainstay of endovascular therapy for infrapopliteal chronic limb-threatening ischemia (CLTI), but outcomes have not been well characterized using high-quality data. The aim of this meta-analysis was to provide an updated benchmark for rates of primary patency and binary restenosis after PTA using prospectively collected, predominantly core-lab adjudicated randomized controlled trial (RCT) data. MATERIALS AND METHODS: MEDLINE, EMBASE, Cochrane Central, and ClinicalTrials.gov were queried for RCTs published through November 2022 using PTA as a control arm and including patients with infrapopliteal CLTI. Studies were excluded if >25% of patients had intermittent claudication, other vessels were included, or primary patency or binary restenosis were not outcomes. Outcomes were analyzed using random effects models. This analysis was publicly registered (PROSPERO ID#394543). No funding was utilized. RESULTS: Seventeen RCTs were included (1048 patients, 1279 lesions). Pooled primary patency rates using data from 6 RCTs were 68% at 6 months (95% confidence interval [CI]=45%-84%) and 66% at 12 months (95% CI=51%-79%). Pooled binary restenosis rates using data from 11 RCTs were 54% at 6 months (95% CI=33%-73%) and 60% at 9 to 12 months (95% CI=39%-78%). Significant heterogeneity was present in all outcomes (I2>50%, p<0.0001). Publication bias was not observed (Egger's p>0.1). CONCLUSIONS: This meta-analysis provides estimates for binary restenosis and primary patency following PTA utilizing prospectively collected, predominantly core-lab adjudicated data. Results demonstrate 1-year primary patency rates that are 10% to 20% higher than what has been historically used in power calculations. These new estimates will help facilitate more accurate power analysis for future RCTs.Clinical ImpactRates of primary patency and binary restenosis after percutaneous transluminal angioplasty (PTA) have not been well-described using high-quality data, and investigators have been utilizing estimates of 40% to 50% and 45% to 65%, respectively, when performing power calculations for trials. This meta-analysis demonstrates using high-quality, prospectively collected, and predominantly core-lab adjudicated randomized controlled trial data that actual rates of primary patency are closer to 60% up to 1 year following PTA and provides the first meta-analysis estimate of binary restenosis rates up to 1 year after PTA. These estimates will help facilitate more accurate power calculations for future RCTs in this space.
引用
- Snyder DJ, Zilinyi RS, Pruthi S, et al. Percutaneous Transluminal Angioplasty for Infrapopliteal Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-analysis of Primary Patency and Binary Restenosis Rates. J Endovasc Ther. 2023. PMID: 38008929. doi:10.1177/15266028231212133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。